Vitamin E (High Dose) and Vitamin K: Important Interaction

Vitamin K functions as a cofactor for gamma-glutamyl carboxylase, the enzyme responsible for activating clotting factors II (prothrombin), VII, IX, and X by adding carboxyl groups to their glutamic acid residues. After donating its electrons in this carboxylation reaction, vitamin K is oxidized to vitamin K epoxide, which must be recycled back to its active quinone form by the enzyme vitamin K epoxide reductase (VKORC1). High-dose alpha-tocopherol (vitamin E) inhibits this recycling step by competing with vitamin K quinone at the VKORC1 binding site. At doses below 200 IU, the competitive inhibition is insufficient to meaningfully reduce clotting factor activity. Above 400 IU daily, the inhibition becomes dose-dependent and clinically relevant — prothrombin time (PT) elongates and INR rises as functional vitamin K availability declines.

The antagonism operates through a second parallel mechanism: high concentrations of alpha-tocopherol directly inhibit the vitamin K-dependent carboxylase enzyme itself, independent of VKORC1 interference. This dual inhibition — blocking both the recycling of vitamin K and its downstream enzymatic activity — means that even increasing dietary vitamin K intake may not fully compensate for very high vitamin E doses (above 800 IU). The clinical consequence is measurable: PMID 15585762 documented prolonged prothrombin times in subjects receiving 1200 IU alpha-tocopherol daily, with the effect reversible upon discontinuation or vitamin K supplementation. At moderate vitamin E doses (200-400 IU), ensuring adequate dietary vitamin K (120-150 mcg/day from green leafy vegetables) or supplemental K is generally sufficient to maintain normal coagulation. Above 800 IU, the interaction warrants laboratory monitoring of PT/INR regardless of K intake.